RxDoctor Payments DataLook up a doctor →

Christian Sanfilippo, MD

Retina Specialist · Encino, CANPI 1851653547

Payments from drug & device makers

$825,653in general payments, 2019–2025

Across 240 payments — averaging $3440.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$764K
  • AbbVie$40K
  • Janssen Research & Development, LLC$17K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Genentech USA, Inc.$727
  • Alimera Sciences, Inc.$291
  • plus $2K from 17 others

What the payments were for

  • Grants$1,20018%
  • Food & beverage$5,39382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$825,653 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$3,466,516
Medicare patients
1,170
Services billed
38,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium27$16,006
Prednisolone Acetate191$7,724
IlevroNepafenac21$7,648
Bromfenac Sodium40$6,179
CombiganBrimonidine Tartrate/Timolol11$2,547
Difluprednate19$1,622
MoxifloxacinMoxifloxacin Hcl53$994
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat44$794
Brimonidine Tartrate35$463
Atropine Sulfate12$409
Ketorolac Tromethamine28$400
Timolol Maleate27$240
Latanoprost50$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$125$7,64821 claims
AbbVieCombigan$39,672$2,54711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 retina specialist providers in California.

Other retina specialist in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →